openPR Logo
Press release

Actos Bladder Cancer Lawsuits Continue to Mount as Attorneys Push for Consolidation

12-10-2011 09:25 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen, LLP

With new Actos bladder cancer lawsuits being filed every day, the plaintiffs and their attorneys are urging for the consolidation of these cases. Some 3500 Actos lawsuits have been filed in state and federal courts across the country, including Illinois, New York, New Jersey, Ohio and California. The law firm of Nadrich & Cohen LLP is currently investigating claims from Actos users in all 50 states who claim they developed bladder cancer after taking the Type 2 diabetes drug.

The U.S. Food and Drug Administration first issued a warning about the Actos bladder cancer link in September 2010. In July 2011, the FDA issued new safety warnings after the results of a ten-year research study indicated that Actos users are more likely to develop bladder cancer if they take the drug for one year or longer. The drug has already been pulled off the shelves in France and Germany but as of yet, there has been no word on whether the FDA will issue a recall in the U.S. In November 2011, the European Medical Agency issued a statement citing its ongoing support of Actos for use in treating diabetes patients only when other forms of treatment fail to work.

Actos brought in nearly $5 billion in revenue in 2010 for Takeda Pharmaceuticals, the Japanese company that manufactures the drug. Takeda has yet to comment on the pending litigation. The FDA recently opted to delay its review of a new Type 2 diabetes drug which combines Actos with another drug, algoliptin.

In an effort to reach out to Actos bladder cancer patients across the county, national law firm Nadrich & Cohen LLP has created www.SideEffectActos.com, an online resource center. Visitors to the site can get the latest news, updates and information on the Actos litigation and complete a confidential contact form to schedule a free initial case evaluation. The firm’s Injury Hotline is also available 24 hours a day, 7 days a week by calling 1-800-722-0765.

If you or someone you love has developed bladder cancer after taking Actos, contact Nadrich & Cohen today to discuss your claim. All cases are accepted on a contingency basis, meaning there is never a fee unless a money judgment is recovered on your behalf.

###

Contact:

Jennifer Poole

National Client Intake Coordinator

Nadrich & Cohen LLP

12100 Wilshire Blvd., Suite 1250

Los Angeles, CA 90025

800-718-4658

www.PersonalInjuryLawCal.com

Nadrich & Cohen LLP is a national law firm specializing in representing clients who've been injured by defective medical devices, harmful products, car accidents, motorcycle accidents, bicycle accidents and dog bites.

Nadrich & Cohen LLP
12100 Wilshire Blvd. Suite 1250
Los Angeles, CA 90025
Jennifer Poole
National Client Intake Coordinator
800-718-4658
www.personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Actos Bladder Cancer Lawsuits Continue to Mount as Attorneys Push for Consolidation here

News-ID: 203432 • Views:

More Releases from Nadrich & Cohen, LLP

Johnson & Johnson Defends Withdrawal of PMA for Rejected Hips
Nadrich & Cohen, LLP reports that Johnson & Johnson is defending its withdrawal of a PMA for a rejected metal hip device that was reportedly sold overseas. Los Angeles, CA, February 16, 2012 – The Johnson & Johnson Company is facing more criticism after a recent New York Times article revealed that the company continued to market a metal hip resurfacing system overseas, despite the fact that the FDA failed to
New Actos Bladder Cancer Resource Center Offers Answers to Concerned Patients
Los Angeles, CA, December 6, 2011 -- Nadrich & Cohen LLP, a prominent national law firm, has established a new website geared towards helping Actos users who developed bladder cancer after taking the drug. Visitors to the new site, www.SideEffectActos.com, can find the latest updates, news and information on the Actos bladder cancer litigation. The link between Actos and bladder cancer first came to light in September 2010, when the
New Vaginal Mesh Safety Recommendations Issued
National law firm Nadrich & Cohen LLP is endorsing new recommendations issued by the American College of Obstetricians and Gynecologists (ACOG) and the American Urogynecologic Society (AUGS) regarding the use of transvaginal mesh to treat pelvic organ prolapse in certain women. In a joint statement, the two organizations called for physicians to limit their use of vaginal mesh only to high-risk women for whom other treatment methods would not be
Actos Bladder Cancer Lawsuits Expected to Top 10,000
Los Angeles, CA, December 2, 2011 --- The number of lawsuits stemming from Actos bladder cancer claims may reach more than 10,000, according to a Bloomberg report. In response, national law firm Nadrich & Cohen, LLP has launched a new Actos bladder cancer resource website to assist patients in filing their claims. Visitors to www.SideEffectActos.com can read up on the link between Actos and bladder cancer, get the latest updates

All 5 Releases


More Releases for Actos

Initial Hearing Scheduled in Federal Actos Bladder Cancer Litigation
Nadrich & Cohen, LLP reports that the federal judge presiding over the consolidated Actos bladder cancer cases has scheduled the first hearing in the pending litigation. Los Angeles, CA, February 14, 2012 – Judge Rebecca Doherty issued an order on Monday announcing that she would be appointing lead counsel for the consolidated Actos lawsuits following a March 22nd status conference set to take place in Lafayette, LA. Judge Doherty was assigned
Federal Panel Votes to Consolidate Actos Bladder Cancer Lawsuits
Nadrich & Cohen LLP reports that a federal judicial panel has voted to consolidate pending Actos bladder cancer claims into a multidistrict litigation for pretrial proceedings. Los Angeles, CA, January 5, 2012 – Plaintiffs in the Actos bladder cancer litigation have successfully moved to have the federal lawsuits consolidated into a multidistrict litigation for pretrial proceedings. The cases will be transferred to the Western District Court of Louisiana, with the
More Actos Bladder Cancer Lawsuits Filed in Los Angeles
Nadrich & Cohen LLP reports that new lawsuits have been filed in Los Angeles against the maker of Actos by two patients who allege the drug caused bladder cancer. Los Angeles, CA, December 30, 2011 – As Takeda Pharmaceuticals continues to battle litigation over its Type 2 diabetes drug Actos, three additional lawsuits were filed in a Los Angeles court. The newest claims join the thousands of other Actos lawsuits that
Takeda Pharmaceuticals, Eli Lilly Face Actos Class Action Lawsuit in Canada
Los Angeles, CA, December 22, 2011 – A class action lawsuit was filed in an Ontario Superior Court against Japanese drug-maker Takeda Pharmaceuticals, alleging that the company knew its popular Type 2 diabetes drug Actos causes bladder cancer. The class action suit also names Eli Lilly as a defendant. According to court records, the lead plaintiff in the action is a Toronto woman who began taking Actos in 2002. The
Despite Bladder Cancer Lawsuits, Generic Actos May Hit Market Next Year
Takeda Pharmaceuticals, the manufacturer of Type 2 diabetes drug Actos, may face stiff competition from generic competitors when the drug’s patent expires in August 2012. The Japanese drug-maker also faces trouble on another front in the form of thousands of lawsuits filed by Actos users who allege the drug caused them to develop bladder cancer. Takeda has previously settled lawsuits from a number of drug manufacturers which would allow the
Nadrich & Cohen Now Reviewing Actos Bladder Cancer Claims
Los Angeles, CA, December 12, 2011 – Nadrich & Cohen LLP, a prominent national law firm, is now reviewing claims from Actos users in all 50 states who developed bladder cancer after taking the drug. In an effort to connect with even more Actos users across the country, the firm has established an online resource center at www.SideEffectActos.com. Actos was approved by the U.S. Food and Drug Administration to treat adults